T. Rowe Price Associates
CLVS

T. Rowe Price Associates’s Clovis Oncology, Inc. CLVS Stock Holding History

T. Rowe Price Associates’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85,900
Closed -$103K – 3028
2022
Q3 		$103K Sell
85,900
-37,550
-30% -$58.5K ﹤0.01% 2721
2022
Q2 		$222K Sell
123,450
-49,490
-29% -$73K ﹤0.01% 2563
2022
Q1 		$349K Buy
172,940
+13,100
+8% +$25.7K ﹤0.01% 2488
2021
Q4 		$433K Buy
159,840
+59,800
+60% +$221K ﹤0.01% 2459
2021
Q3 		$446K Buy
100,040
+22,646
+29% +$109K ﹤0.01% 2431
2021
Q2 		$449K Sell
77,394
-4,496
-5% -$26.3K ﹤0.01% 2434
2021
Q1 		$575K Buy
81,890
+8,604
+12% +$57.7K ﹤0.01% 2305
2020
Q4 		$352K Buy
73,286
+14,423
+25% +$73K ﹤0.01% 2372
2020
Q3 		$343K Sell
58,863
-6,404
-10% -$38.3K ﹤0.01% 2239
2020
Q2 		$441K Sell
65,267
-12,075
-16% -$91.4K ﹤0.01% 2096
2020
Q1 		$492K Sell
77,342
-8,085
-9% -$64.9K ﹤0.01% 1997
2019
Q4 		$891K Buy
85,427
+34,286
+67% +$249K ﹤0.01% 1937
2019
Q3 		$201K Buy
51,141
+21,416
+72% +$173K ﹤0.01% 2384
2019
Q2 		$442K Buy
29,725
+182
+0.6% +$3.29K ﹤0.01% 2158
2019
Q1 		$733K Buy
29,543
+3,200
+12% +$80.2K ﹤0.01% 1973
2018
Q4 		$473K Sell
26,343
-154,745
-85% -$3.16M ﹤0.01% 2099
2018
Q3 		$5.32M Sell
181,088
-135,744
-43% -$5.26M ﹤0.01% 1447
2018
Q2 		$14.4M Sell
316,832
-23,839
-7% -$1.16M ﹤0.01% 1282
2018
Q1 		$18M Sell
340,671
-543,306
-61% -$31.7M ﹤0.01% 1218
2017
Q4 		$60.1M Sell
883,977
-468,728
-35% -$32.8M 0.01% 798
2017
Q3 		$111M Sell
1,352,705
-680,558
-33% -$54M 0.02% 600
2017
Q2 		$190M Buy
2,033,263
+1,759,645
+643% +$108M 0.03% 449
2017
Q1 		$17.4M Sell
273,618
-165,788
-38% -$10.1M ﹤0.01% 1211
2016
Q4 		$19.5M Sell
439,406
-843,388
-66% -$29.7M ﹤0.01% 1154
2016
Q3 		$46.2M Sell
1,282,794
-238,000
-16% -$5.11M 0.01% 834
2016
Q2 		$20.9M Sell
1,520,794
-43,811
-3% -$640K ﹤0.01% 1087
2016
Q1 		$30M Sell
1,564,605
-18,290
-1% -$387K 0.01% 954
2015
Q4 		$55.4M Sell
1,582,895
-353,978
-18% -$22.8M 0.01% 729
2015
Q3 		$178M Sell
1,936,873
-288,764
-13% -$25M 0.04% 433
2015
Q2 		$196M Sell
2,225,637
-49,845
-2% -$4.27M 0.04% 453
2015
Q1 		$169M Buy
2,275,482
+62,078
+3% +$4.38M 0.03% 472
2014
Q4 		$124M Buy
2,213,404
+945,153
+75% +$49.7M 0.03% 554
2014
Q3 		$57.5M Sell
1,268,251
-34,800
-3% -$1.45M 0.01% 784
2014
Q2 		$54M Buy
1,303,051
+226,025
+21% +$11.6M 0.01% 840
2014
Q1 		$74.6M Buy
1,077,026
+165,171
+18% +$12.1M 0.02% 721
2013
Q4 		$55M Buy
911,855
+175,300
+24% +$9.54M 0.01% 805
2013
Q3 		$44.8M Sell
736,555
-148,888
-17% -$10.6M 0.01% 856
2013
Q2 		$59.3M Buy
+885,443
New +$39.8M 0.02% 732

Other funds holding CLVS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CAS
Coppell Advisory Solutions Coppell, Texas $170M AUM 13.42% 1-Year Est. Return
CASC
Coppell Advisory Solutions Corp Coppell, Texas $531M AUM
STB
S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
FFWM
Future Financial Wealth Management Cincinnati, Ohio $160M AUM 21.24% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

T. Rowe Price Associates's CLVS Position: Q4 2022 in Review

T. Rowe Price Associates sold out of Clovis Oncology, Inc. (CLVS) in Q4 2022, closing a stake of 85,900 shares — an estimated $103K sold.

T. Rowe Price Associates first reported a position in CLVS in Q2 2013 and held it in 38 quarters. The position peaked at $196M in Q2 2015. 15 funds tracked by Wall St. Rank hold CLVS as of Q4 2022.

  • T. Rowe Price Associates reported no remaining Clovis Oncology, Inc. position as of Q4 2022 after selling out during the quarter.
  • T. Rowe Price Associates sold 85,900 Clovis Oncology, Inc. shares in Q4 2022, an estimated $103K.
  • T. Rowe Price Associates first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 38 quarters.
  • T. Rowe Price Associates's Clovis Oncology, Inc. position peaked at $196M in Q2 2015.
  • 15 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2022.

Based on T. Rowe Price Associates's 13F filing for Q4 2022, filed 14 Feb 2023.